EDUFLUVAC

EDUcate inFLUenza VACcine

Welcome to EDUFLUVAC, a collaborative project funded under the European Commission (EC) 7th Framework Programme (FP7) and coordinated by the European Vaccine Initiative (EVI).  The four-year project was initiated in November 2013 and has an overall budget of € 4.6 million.  The project is the joint effort of leading European experts from academia and industry with unique and specific technological expertise in vaccine development.  

The EDUFLUVAC project aims at developing a “universal” influenza vaccine that can provide longer-lasting and broader protection against multiple strains of influenza virus.  EDUFLUVAC will provide the proof of principle of a novel influenza vaccine concept that does not have to be updated annually, does not have to be manufactured on an annual basis, and will not require an annual vaccination campaign.  It will also provide an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, could manufacture rapidly high quantities of vaccine. 

The aimed level of broad protection will reduce the burden of disease that influenza imposes across Europe and other regions on an annual basis.

 

Group picture taken at the EDUFLUVAC Kick-Off Meeting in Heidelberg on 20 November 2013.

This project has been funded with support from the European Commission under Grant agreement no: 602640

This website reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.


News

23 June 2016

The following products are now available on the NIBSC website:

The following products are now available on the The National Institute for Biological Standards and Control (NIBSC) website:

Influenza Virus Infectious NIBRG-306 ( Influenza Reagent )

23-06-2016 01:00 AM BST

17 June 2016

EVI moves to new address

As of 15 June 2016 EVI is domiciled at:

European Vaccine Initiative
UniversitätsKlinikum Heidelberg
Vossstrasse 2, Geb. 4040
69115 Heidelberg, Germany

14 June 2016

VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2)

European public and private organisations are collaborating in VAC2VAC, a new project funded by the Innovative Medicines Initiative (IMI2) to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods.